TIDMSYNC

RNS Number : 6466U

Syncona Limited

02 August 2022

Syncona Limited

Result of Annual General Meeting

2 August 2022

At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2022 Annual General Meeting' dated 30 June 2022 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 12 were proposed as Ordinary Resolutions. Resolution 13 was proposed as a Special Resolution and Resolution 14 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

 
 No   Resolution                      For       Discretion    Against      Abstain 
                                                                          (withheld) 
      Receive and consider 
       the Annual Audited 
       Financial Statements 
       of the Company for 
       the year ended 31 
       March 2022, together 
       with the Reports 
       of the Directors 
 1     and Auditors thereon       464,372,350      (0)        189,929       7,875 
                                    (99.96%)       (0%)       (0.04%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Re-appointment of 
       Deloitte LLP (Guernsey 
 2     Branch) as Auditors        464,325,349      (0)        53,133       191,672 
                                    (99.99%)       (0%)       (0.01%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Authorise the Directors 
       to determine the 
       remuneration of the 
 3     Auditors                   464,558,338      (0)         9,578        2,238 
                                    (99.99%)       (0%)       (0.01%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Re-elect Melanie 
 4     Gee as a Director          463,062,580      (0)       1,490,199     17,375 
                                    (99.68%)       (0%)       (0.32%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Elect Julie Cherrington 
 5     as a Director              464,536,562      (0)         4,217       29,375 
                                    (99.99%)       (0%)       (0.01%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Elect Cristina Csimma 
 6     as a Director              464,536,562      (0)         4,217       29,375 
                                    (99.99%)       (0%)       (0.01%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Re-elect Virginia 
 7     Holmes as a Director       463,062,580      (0)       1,490,199     17,375 
                                    (99.68%)       (0%)       (0.32%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Re-elect Rob Hutchinson 
 8     as a Director              463,029,675      (0)       1,523,104     17,375 
                                    (99.67%)       (0%)       (0.33%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Re-elect Kemal Malik 
 9     as a Director              463,020,330      (0)       1,523,104     26,720 
                                    (99.67%)       (0%)       (0.33%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Re-elect Gian Piero 
 10    Reverberi as a Director    463,028,580      (0)       1,521,854     19,720 
                                    (99.67%)       (0%)       (0.33%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Approve the report 
       on implementation 
       of the Remuneration 
       Policy for Non-Executive 
 11    Directors                  463,065,971      (0)       1,475,563     28,620 
                                    (99.68%)       (0%)       (0.32%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Authority to allot 
 12    and issue shares           464,193,797      (0)        346,067      30,290 
                                    (99.93%)       (0%)       (0.07%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Authorise the Company 
       to purchase its own 
 13    shares                     464,346,845      (0)        211,264      12,045 
                                    (99.95%)       (0%)       (0.05%) 
     --------------------------  ------------  -----------  ----------  ------------ 
      Disapply pre-emption 
 14    rights                     456,459,320      (0)       8,088,893     21,941 
                                    (98.26%)       (0%)       (1.74%) 
     --------------------------  ------------  -----------  ----------  ------------ 
 

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

The full text of the resolutions can be found in the Notice, which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/ .

Enquiries

Syncona Limited

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 7714 916615

FTI Consulting

Ben Atwell / Julia Bradshaw / Tim Stamper

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com .

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUPUQPRUPPGGP

(END) Dow Jones Newswires

August 02, 2022 07:28 ET (11:28 GMT)

Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Ago 2022 a Sep 2022 Haga Click aquí para más Gráficas Syncona.
Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Sep 2021 a Sep 2022 Haga Click aquí para más Gráficas Syncona.